Amarin Corp Plcuk (AMRN) Total Current Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Total Current Liabilities of $179.6 million for Q1 2026, up 10.61% year-over-year from $162.4 million in Q1 2025, and down 7.62% quarter-over-quarter from $194.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Total Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Total Current Liabilities data on file, last reported at $179.6 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $179.6 million, up 10.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $179.6 million (up 10.61% YoY), and the FY2025 annual result was $194.5 million, up 8.06% from the prior year.
- Total Current Liabilities eased to $179.6 million in Q1 2026 per AMRN's latest filing, from $194.5 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $361.6 million in Q2 2022 and troughed at $162.4 million in Q1 2025.
- A 5-year average of $234.8 million and a median of $230.5 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities sank 30.6% in 2024, then gained 10.61% in 2026.
- A 5-year view of Total Current Liabilities shows it stood at $259.5 million in 2022, then slipped by 0.08% to $259.3 million in 2023, then slumped by 30.6% to $179.9 million in 2024, then increased by 8.06% to $194.5 million in 2025, then decreased by 7.62% to $179.6 million in 2026.
- Business Quant data shows AMRN's Total Current Liabilities at $179.6 million in Q1 2026, $194.5 million in Q4 2025, and $182.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -30.24 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 179.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179.64 Mn |
| Dec 31, 2025 | 194.46 Mn |
| Sep 30, 2025 | 182.23 Mn |
| Jun 30, 2025 | 185.95 Mn |
| Mar 31, 2025 | 162.41 Mn |
| Dec 31, 2024 | 179.95 Mn |
| Sep 30, 2024 | 201.55 Mn |
| Jun 30, 2024 | 230.54 Mn |
| Mar 31, 2024 | 224.38 Mn |
| Dec 31, 2023 | 259.28 Mn |
| Sep 30, 2023 | 266.69 Mn |
| Jun 30, 2023 | 270.93 Mn |
| Mar 31, 2023 | 244.24 Mn |
| Dec 31, 2022 | 259.48 Mn |
| Sep 30, 2022 | 287.36 Mn |
| Jun 30, 2022 | 361.57 Mn |
| Mar 31, 2022 | 300.57 Mn |
| Dec 31, 2021 | 370.68 Mn |
| Sep 30, 2021 | 364.75 Mn |
| Jun 30, 2021 | 370.44 Mn |